Thursday, April 25, 2013 10:55:49 AM
Not sure what brand you are taking but here is the breakdown for Norwegian Gold 1000mg EPA
30 pills costs about $40.00 retail. One pill is 1200mg and by lab analysis (IFOS) contains about 1046 actual mgs of EPA. So approximately 87% EPA. Online it can be had for $34.00 per 30 but after you add in shipping you are right back to the full retail price. At $40.00/30 pills we get $1.33 per approx 1gm of EPA
Yesterday I renewed my script for Vascepa. It is an off label script and there is no coverage for me. Vascepa is a 1000mg pill with 96% or greater EPA concentration. So each pill contains 960mg of EPA
Cost with coupon was $35.48/30 pills or $1.18 per approx 1gm EPA
Pretty close. Norwegian Gold is .0012715 per milligram ( $1.33/1046)
Vascepa is .001229 per milligram ( $1.18/960)
Vascepa is alittle cheaper even for out of pocket and is stocked at my local CVS. No wait. Factor in insurance coverage for those covered under the current indication and it is a no brainer. Norwegian Gold flavors their fish oil and I suspect there is a reason for that! lol
30 pills costs about $40.00 retail. One pill is 1200mg and by lab analysis (IFOS) contains about 1046 actual mgs of EPA. So approximately 87% EPA. Online it can be had for $34.00 per 30 but after you add in shipping you are right back to the full retail price. At $40.00/30 pills we get $1.33 per approx 1gm of EPA
Yesterday I renewed my script for Vascepa. It is an off label script and there is no coverage for me. Vascepa is a 1000mg pill with 96% or greater EPA concentration. So each pill contains 960mg of EPA
Cost with coupon was $35.48/30 pills or $1.18 per approx 1gm EPA
Pretty close. Norwegian Gold is .0012715 per milligram ( $1.33/1046)
Vascepa is .001229 per milligram ( $1.18/960)
Vascepa is alittle cheaper even for out of pocket and is stocked at my local CVS. No wait. Factor in insurance coverage for those covered under the current indication and it is a no brainer. Norwegian Gold flavors their fish oil and I suspect there is a reason for that! lol
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
